Value of COX-2 and HER-2 in judging condition and prognosis in non-small cell lung cancer patients

Clinical Oncology and Cancer Research - Tập 7 - Trang 200-205 - 2010
Lei Yang1, Jun-guo Lu1, Qing-he Tan1, Jin-zhi Wei1, Xiao-dong Zhang1, Hong-bing Gu1
1Department of Medical Oncology, Nantong Tumor Hospital, Nantong, Jiangsu Province, China

Tóm tắt

To investigate the expressions of cyclooxygenase 2 (COX-2) and human epidermal growth factor receptor-2 (HER-2) in non-small cell lung cancer (NSCLC) and their clinical significance in identifying the progression and prognosis of the NSCLC patients. Immunohistochemical indirect method was used to detect the expressions of the COX-2 and HER-2 protein in 54 NSCLC specimens, 16 paraneoplastic specimens, and 10 normal tissue specimens. The positive rates of COX-2 and HER-2 protein expressions were respectively 75.9% and 40.7% in the NSCLC specimens, 25% and 12.5% in the paraneoplastic specimens, and 0 in the normal tissue. The COX-2 protein expression in lung cancer (LC) was not only related to the smoking habit of the patients and histological grades of LC, but also to the TNM stages, and lymphatic metastasis (P < 0.05). HER-2 protein expression closely correlated to the pathologic types, histological grades, TNM stages, and lymphatic metastasis (P < 0.05). The result of univariate analysis showed that all the histological grades, TNM stages, lymphatic metastasis, and expressions of COX-2/HER-2 correlated to the prognosis of NSCLC patients (mean of P value < 0.01). The multivariate survival analysis indicated that there were significant diff erences in comparison of the survival time between the COX-2 (++/+++) /HER-2 (++/+++) and the COX-2 (−/+)/HER-2 (−/+) groups (P < 0.001), suggesting the COX-2/HER-2 was a negative prognostic factor. COX-2 and HER-2 are valuable in identifying the progression of NSCLC and predicting the prognosis of NSCLC patients. COX-2 and HER-2 are useful for judging the NSCLC patient’s condition, and are of great value to the decision of NSCLC prognosis.

Tài liệu tham khảo

Soslow RA, Dannenbexg AJ, Rush D, et al. COX-2 pressed in human pulmonary, colonic, and mammary turn. Cancer 2000; 89: 2637–2645.

Hammock L, Lewis M, Phillips C, et al. Strong HER-2/neu protein overexression by immunohistochemistry often dose not predict oncogene amplification by fluorescence in situ hybridization. Hum pathol 2003; 34: 1043–1405.

Ren XD, Lü YQ, Ye KH, et al. The anti-tumor molecular mechanisms of non-steroid anti-inflammatory drugs. Zhongguo Yaolixue Tongbao 2005; 21: 527–531 (Chinese).

Chen FC, Pan Q, Zhang YX, et al. Roles of cyclooxygenase-2 and caspase-3 expression in pathogenesis of lung carcinoma: an experiment. Zhonghua Yixue Zazhi 2005; 85: 1916–1920 (Chinese).

Laga AC, Zander DS, Cagle PT. Prognostic significance of cyclooxygenase 2 expression in 259 cases of non small cell lung cancer. Arch Pathol LabMed 2005; 129: 1113–1117.

Hida T, Yatabe Y, Achiwa H, et al. Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. Cancer Res 1998; 58: 3761–3764.

Zhang YX, Lai BT, Chen HL, et al. Induction of pulmonary precancerous lesions by tobacco-specific NNK in Wistar rats. Zhongguo Feiai Zazhi 2006; 9: 152–156 (Chinese).

Varshney D, Zhou YY, Geller SA, et al. Determination of Her-2 status and chromosome 17 polysomy in breast carcinomas comparing Herceptest and Path Vysion FISH assay. Am J Clin Pathol 2004; 121: 70–72.

Nakamura H, Kawasaki N, Taguohi M, et al. Association of HER-2 overexpression with Prognosis in nonsmall cell lung carcinoma: a meta analysis. Cancer 2005; 103: 1865–1873.

Deng ZC, Ge D, Zhang DH, et al. Expression of HER-2 family in lung cancer. Zhonghua Jiehehehuxi Zazhi 2002; 25: 207–209 (Chinese).

Menard S, Pupa SM, Campiglio M, et al. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22: 6570–6572.

Tan D, Deeb G, Wang J, et al. HER-2/neu protein expression and gene alteration in stage I-IIIA non-smallcell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization. Diagn Mol Pathol 2003; 12: 201–201.

Vallhohmer D, Brabender J, Yang DY, et al. Sex differences in the predictive power of the molecular prognostic factor HER2/neu in patients with non-small-cell lung cancer. Clin Lung Cancer 2006; 7: 332–337.

Lal P, Salazar PA, Hudis CA, et al. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single 2 institution experience of 279 cases and comparison of dual color and single color scoring. Am J Clin Pathol 2004; 121: 631–635.

Zhang J, Chen LZ, Lü YL, et al. Correlations of differentiation and metastasis with amplification and expression of Her-2/neu oncogene in human lung cancer. Zhongguo Zhongliu Linchuang 1997; 24: 452–455 (Chinese).

Richardson CM, Sharma RA, Cox G, et al. Epidermal growth factor receptors and cyclooxygenase-2 in the pathogenesis of non-small cell lung cancer: potential targets for chemoprevention and systemic therapy. Lung Cancer 2003; 39: 1–13.

Lonardo F, Dragnev KH, Freemantle SJ, et al. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin Cancer Res 2002; 8: 54–60.

Niki T, Kohno T, Iba S, et al. Frequent co-localization of COX-2 and laminin-5 gamma2 chain at the invasive front of early2stage lung Adenocarcinomas. Am J Pathol 2002; 160: 1129–1141.

Brown JR, DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005; 23: 2840–2855.

Andrew J, Scott M, Jason R, et al. Cyclooxygenase-2 and epidermal growth factor receptor receptor:pharmacologic targets for chemoprevention. J Clin Oncol 2005; 23: 254–266.

Thông tin
Thông tin xuất bản

Clinical Oncology and Cancer Research

Tập 7

200-205

Thông tin tác giả